Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis

The document is a scientometric analysis of 2,118 publications from 2011 to 2020, studying the relationship between androgen receptors (ARs) and breast cancer. The United States was the leading contributor to this research, with the University of Texas MD Anderson Cancer Center being the most productive institution. The research focus shifted over time from the relationship between molecular types of breast cancer and AR gene expression to the mechanism and signal pathway of AR's action in breast cancer, and then to clinical applications such as therapy and prognosis. The study suggests that ARs may be a potential prognostic index and therapeutic target for some types of breast cancer, including Triple-Negative Breast Cancer (TNBC). The document also highlights that AR overexpression can induce resistance to Tamoxifen, a common breast cancer treatment, and suggests Enzalutamide as a possible treatment for AR-expressing TNBC. Future research should focus on emerging themes such as “androgen receptor expression”, “growth-factor receptor”, “neoadjuvant chemotherapy”, and “tumor-infiltrating lymphocyte”.